NCT03289949View on ClinicalTrials.gov

The Neurobiological Effect of 5-HT2AR Modulation

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2030

Conditions
Basic Science
Interventions
DRUG

Psilocybine

Oral dose of psilocybine.

DRUG

Ketanserin

Oral dose of ketanserin.

Trial Locations (1)

2100

RECRUITING

Neurobiology Research Unit, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Gitte Moos Knudsen

OTHER